Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Pharmaceutical composition comprising periodontal tissue-derived pluripotent stem cells for prevention or treatment of male infertility

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Publication Date:
    March 04, 2025
  • Additional Information
    • Patent Number:
      12239,668
    • Appl. No:
      17/609460
    • Application Filed:
      May 08, 2020
    • Abstract:
      The present invention relates to a pharmaceutical composition including vitrified periodontal tissue-derived mesenchymal stem cells for prevention or treatment of male infertility. The pharmaceutical composition for prevention or treatment of male infertility according to the present invention recovers sex hormone levels in seminiferous tubules of atrophic testes and blood to normal levels through improvement in the activity of lipid metabolism enzymes in the liver, thereby exhibiting remarkable prophylactic and therapeutic effects on male infertility. In addition, the periodontal tissue-derived mesenchymal stem cells which are an active ingredient in the present invention can be obtained in the most non-invasive manner and as such, are expected to be advantageously used as a cell therapy product for male infertility.
    • Inventors:
      INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (Jinju-si, KR); STEMCENTRIC CO., LTD. (Anyang-si, KR)
    • Assignees:
      Industry-Academic Cooperation Foundation Gyeongsang National University (KR), Stemcentric Co., Ltd. (KR)
    • Claim:
      1. A method for treating male infertility in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising periodontal tissue-derived mesenchymal stem cells.
    • Claim:
      2. The method of claim 1 , wherein the pharmaceutical composition is administered three times or more at an interval of 1 to 3 weeks.
    • Claim:
      3. The method of claim 1 , wherein the pharmaceutical composition is administered at a dose effective to deliver about 10 4 to about 10 10 periodontal tissue-derived mesenchymal stem cells to the subject.
    • Claim:
      4. A method for treating male infertility in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a therapeutic agent comprising periodontal tissue-derived mesenchymal stem cells.
    • Claim:
      5. The method of claim 4 , wherein the therapeutic agent is administered three times or more at an interval of 1 to 3 weeks.
    • Claim:
      6. The method of claim 4 , wherein the therapeutic agent is administered at a dose effective to deliver about 10 4 to about 10 10 periodontal tissue-derived mesenchymal stem cells to the subject.
    • Patent References Cited:
      8980847 March 2015 Kim et al.
      2018/0055887 March 2018 Lu et al.
      2006-115837 May 2006
      10-2013-0035091 April 2013
      10-2015-0069469 June 2015
      10-1551900 June 2015
      WO-2019074046 April 2019



    • Other References:
      English translation of Hokkaido University, WO 2019/074046 A1, Apr. 2019. cited by examiner
      Dave et al., “Dental tissue-derived mesenchymal stem cells: applications in tissue engineering,” Critical Reviews in Biomedical Engineering 46(5):429-468, 2018. cited by examiner
      Hassan et al., “Evaluation of mesenchymal stem cells in treatment of infertility in male rats,” Stem Cell Research & Therapy 2014, 5: 131, 15 pages. cited by applicant
      International Search Report and Written Opinion, PCT/KR2020/006091, Sep. 8, 2020, 9 pages. cited by applicant
    • Primary Examiner:
      Kosson, Rosanne
    • Attorney, Agent or Firm:
      POLSINELLI PC
    • Accession Number:
      edspgr.12239668